COMPANY

Nammi Therapeutics

HQ: Los Angeles, CA source · nammirx.com ↗

Keywords: cancer Ovarian Cancer Pancreas Cancer Urothelial Carcinoma Renal Cell Carcinoma Hepatocellular Carcinoma Gastrointestinal Cancer Lung Cancer Prostate Cancer Breast Cancer

Location: Los Angeles, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $30M · announced Aug 7, 2024 Company release ↗
Source quote
- Aug 7, 2024 · Company release ↗
  “Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program”

Raises announced in these releases: $30M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Aug 28, 2024 Trial start Phase 1: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma source ↗
Aug 7, 2024 Raise Series B · $30M source ↗

Upcoming milestones

Dec 31, 2027 (ESTIMATED) · Phase 1 · Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma · NCT06582017

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06582017	Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Phase 1	Recruiting	Aug 28, 2024	Dec 31, 2027 (estimated)